Celularity (NASDAQ:CELU) Stock Rating Raised to Hold at Wall Street Zen

Celularity (NASDAQ:CELU) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings upgraded Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has a consensus rating of “Sell”.

Celularity Stock Down 8.0%

NASDAQ:CELU opened at $0.63 on Friday. The firm has a market cap of $20.45 million, a PE ratio of -0.37 and a beta of 0.88. Celularity has a 12 month low of $0.56 and a 12 month high of $2.55. The company’s 50-day moving average price is $1.18 and its two-hundred day moving average price is $1.06.

Celularity (NASDAQ:CELU) last posted its quarterly earnings data on Tuesday, October 20th. The company reported $0.02 earnings per share for the quarter. The firm had revenue of $5.43 million for the quarter.

Institutional Trading of Celularity

An institutional investor recently bought a new position in Celularity stock. C V Starr & Co. Inc. acquired a new position in Celularity, Inc. (NASDAQ:CELU) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity comprises approximately 0.8% of C V Starr & Co. Inc.’s investment portfolio, making the stock its 4th largest position. C V Starr & Co. Inc. owned 2.64% of Celularity as of its most recent SEC filing. Institutional investors own 19.02% of the company’s stock.

About Celularity

Celularity, Inc. (NASDAQ: CELU) is a biotechnology company developing and commercializing therapies and biomaterial products derived from human placental tissue. Its work focuses on regenerative medicine and cellular therapy, including allogeneic, or donor-derived, cell products intended for applications in oncology, immune-mediated diseases, and tissue repair. The company’s research pipeline has included placenta-derived natural killer (NK) cell therapies, such as CYNK-001, an investigational product studied for certain blood cancers, and other cell-based programs designed to address cancer and inflammatory conditions.